Episode Details
What you’ll get out of this episode:
- Exploring the roots of Codagenix: from a 200 sq ft office to a global influencer in the biotech sphere.
- Insights into the potential of synthetic biology in vaccine development.
- Codagenix’s unique approach to code on deoptimization to combat viruses.
- In-depth discussion on Codagenix’s current pipeline: RSV, COVID-19, and beyond.
- The future of Codagenix and its role in cancer therapeutics.
- Fundraising and next steps for the biotech giant.
Watch
Listen
Read
Introduction
The dynamic world of synthetic biology has been breaking barriers and creating opportunities in numerous sectors. In a recent podcast episode, Jared S. Taylor sat down with Rob Coleman, the CEO of Codagenix, to discuss the company’s origin, its current state, and the future of synthetic biology.
A Quick Dive into Rob Coleman’s Background
Coleman’s journey began with his undergraduate studies at Tulane University, followed by a Ph.D. from Stony Brook. His Ph.D. thesis became the technological foundation of Codagenix, a company he co-founded based on the tech he co-invented. As a trained virologist with an MBA, Coleman understands both the scientific and business aspects of Codagenix’s operations.
The Evolution of Codagenix
Starting from a modest office space with just two employees, Codagenix has grown exponentially. With its foundations in the laboratory of Eckard Wimmer, Codagenix has leveraged synthetic biology to design viruses from scratch. Their core technology revolves around modifying the DNA of wild-type viruses, transforming them into live attenuated vaccines.
Current State of Synthetic Biology
According to Coleman, synthetic biology offers immense potential, not just for human health but also in agriculture and green energy sectors. The aim is to design organisms to solve problems, a concept Codagenix has embraced fully, allowing them to design vaccines that tackle dangerous viruses.
Codagenix’s Current Pipeline
Coleman shared details about Codagenix’s two primary projects:
-
RSV Vaccine: Designed for pediatrics, this intra-nasal vaccine targets children aged between six months to five years. With recent surges in RSV cases and limited competition, Codagenix’s RSV vaccine holds immense potential.
-
COVID-19 Vaccine: In collaboration with global partners, Codagenix is currently conducting a placebo control trial to test the efficacy of their intra-nasal COVID vaccine against variants like Omicron.
Dabbling in Animal Health
Beyond human health, Codagenix is exploring the world of animal health, where they design viruses for undisclosed partners. Their platform’s flexibility allows them to target viruses specific to different animals, promising innovative solutions for the animal health sector.
What’s Next for Codagenix
Coleman’s excitement for the company’s future is palpable. Codagenix recently secured a fundraising round of $25 million, which will be instrumental in furthering their innovative projects. Beyond the current pipeline, the company is also looking at utilizing viruses to tackle solid tumors, offering a new perspective in cancer therapy.
Conclusion
Codagenix’s journey, from a small startup to a promising biotech firm, stands as a testament to the potential of synthetic biology. With leaders like Rob Coleman at the helm, the future looks promising, not just for Codagenix but for the broader realm of biotechnology.
WORD FROM OUR SPONSORS:
Our sponsors for this episode are Sage Growth Partners, FlipMD by GoodRX and Quantum Health
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners
Quantum Health is an award-winning consumer healthcare navigation company that delivers an unparalleled consumer experience based on empathy and trust, enabling employers to achieve industry-leading satisfaction rates and independently validated claim savings. Launched in 1999, Quantum Health’s model is based on years of consumer research and the insights learned from guiding millions of consumers and their providers through their healthcare journey. Visit: https://quantum-health.com/ and follow Quantum health on social media – @Quantum Health
To learn more about Codagenix please use the links below:
– Codagenix’s LinkedIn – Codagenix’s Website –
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter –
